Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Gilead’s next steps in oncology

Ambitious top-10 goal in cancer by 2030, with BD focus on early-stage assets that add mechanisms to pipeline

By Stephen Hansen, Director of Biopharma Intelligence
April 19, 2023 10:16 PM UTC

Whether Gilead is now a cancer company is in the eye of the beholder. By its own reckoning, the biopharma, which made its name in infectious disease, is about halfway on the path to its goal for oncology. 

CMO Merdad Parsey believes Gilead Sciences Inc. (NASDAQ:GILD) still needs to invest in its early cancer pipeline to make it a sustainable oncology company over the long term, a position he outlined on The BioCentury Show last month. Much of this focus will come from business development activity across a subset of biology areas...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Arcellx Inc.

Arcus Biosciences Inc.

Astrazeneca plc

Daiichi Sankyo Co. Ltd.

Gilead Sciences Inc.

Roche